Sign in to view Dr. Ashwini’s full profile
or
New to LinkedIn? Join now
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
Sign in to view Dr. Ashwini’s full profile
or
New to LinkedIn? Join now
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
Delhi, India
Sign in to view Dr. Ashwini’s full profile
Dr. Ashwini can introduce you to 10+ people at CliniExperts Research Services
or
New to LinkedIn? Join now
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
7K followers
500+ connections
View mutual connections with Dr. Ashwini
Dr. Ashwini can introduce you to 10+ people at CliniExperts Research Services
or
New to LinkedIn? Join now
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
Sign in to view Dr. Ashwini’s full profile
or
New to LinkedIn? Join now
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
View mutual connections with Dr. Ashwini
or
New to LinkedIn? Join now
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
Sign in to view Dr. Ashwini’s full profile
or
New to LinkedIn? Join now
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
About
With…
Welcome back
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
Articles by Dr. Ashwini
-
AI in MedTech: A Human-Centered Future…Sep 26, 2025
AI in MedTech: A Human-Centered Future…
10
6 Comments -
Surfing the Tariff Tsunami: How do we…Sep 8, 2025
Surfing the Tariff Tsunami: How do we…
20
2 Comments
Activity
7K followers
-
Dr. Ashwini Kumar shared thisEntering India’s healthcare market is often seen as a commercial opportunity. In reality, it is equally a regulatory strategy exercise. For global medical device manufacturers, one of the biggest misconceptions is that Central Drugs Standard Control Organization (CDSCO) import licensing is only about filing the right form. It is not. Correct device classification, selecting the right authorised agent, understanding whether the product is treated as a predicate or new device, and aligning documentation with Indian regulatory expectations, all of these significantly influence timelines and long-term market entry success. As India’s MedTech ecosystem continues to mature under MDR 2017 and evolving CDSCO frameworks, regulatory preparedness is becoming a competitive advantage, not just a compliance requirement. This article by the CliniExperts Services Pvt. Ltd. team breaks down the CDSCO import licensing process in a simplified and structured manner for global manufacturers looking to enter India responsibly and efficiently. A useful read for MedTech founders, regulatory teams, global OEMs, and healthcare businesses evaluating India market entry. Read the article here #MedicalDevices #CDSCO #RegulatoryAffairs #MedTech #HealthcareInnovationDr. Ashwini Kumar shared thisIndia continues to be one of the most attractive markets for global Medical Device companies, driven by its growing healthcare sector and vast opportunities. However, entering the Indian market requires careful regulatory planning under CDSCO and the Medical Devices Rules, 2017. From correct device classification and appointment of an authorized Indian agent to choosing the right MD forms and SUGAM submission pathway, every step plays a critical role in ensuring smooth market entry and regulatory compliance. Read the full article now on our website: https://lnkd.in/gvwQeRZK #MedicalDevices #CDSCO #MedicalDeviceRegulations #IndiaMarket #HealthcareIndustry #RegulatoryCompliance #CliniExpertsHow to Get a CDSCO Import License in India: A Step-by-Step Guide for Foreign Medical Device CompaniesHow to Get a CDSCO Import License in India: A Step-by-Step Guide for Foreign Medical Device Companies
-
Dr. Ashwini Kumar posted thisHow do you convince your first client… when you have no clients to show? This is a question many founders in service businesses eventually face. I faced it early on. When I started CliniExperts Services Pvt. Ltd., there was no portfolio. No case studies. No track record as a company. And in a domain like pharma, medtech, and biotech, that gap matters. Because here, decisions are not just commercial. They are built on trust, compliance, and accountability. Most organisations prefer partners who have already done it before. So the question becomes: Why would someone choose you… when you haven’t worked with a single client yet? My first breakthrough came with Johnson & Johnson. The only reason being: we had clarity in how we approached the problem they were trying to solve back then. At that time, GCP audits were largely conducted through a standard lens, focused on documentation, processes, and compliance checkpoints. We introduced a completely different perspective. Being a doctor, I looked beyond the documentation. I evaluated how clinical investigators were actually following protocols in real-world practice. Not just what was recorded,but how it was being executed. This was not a commonly practiced approach at the time. It brought together: • Clinical understanding • Regulatory expectations • Real-world execution insight In many ways, it redefined how GCP audits could be approached. What we offered was not just a service; It was a deeper layer of domain expertise. More structured. More contextual. More aligned with how regulators and outcomes intersect. That shift made the difference. At the same time, my background, an MD from All India Institute of Medical Sciences, helped build initial credibility. But degrees alone don’t win trust. Execution does. Conviction does. Clarity does. Looking back, I realise something important. Your first client may or may not come because of your past. It comes from how clearly you can define a better way forward. Because in the absence of experience, people don’t buy proof. They buy belief. And that belief is built in how you think, how you communicate, and how responsibly you approach the work. Winning that first project was not just a milestone. It was a responsibility to justify the trust placed before any track record existed. If you reflect on your own journey: What helped you win trust… before you had results to show? #Entrepreneurship #Leadership #StartupJourney #B2B #BuildingTrust
-
Dr. Ashwini Kumar shared thisYour AI medical device just became smarter. Do you need to go back to the regulator every single time it improves? Traditionally, the answer was yes. And that created a major challenge for AI in healthcare. Because unlike traditional medical devices, AI systems are not static. They learn from new data. They improve performance. They adapt over time. But under older regulatory models, even meaningful improvements to an AI-driven medical device could require a completely new submission and review process. Which meant innovation often moved faster than regulation. The US FDA ’s Predetermined Change Control Plan (PCCP), finalised in December 2024, attempts to solve this problem in a very practical way. The idea is surprisingly simple. Before an AI medical device is approved, the company explains to the regulator: • What kinds of future algorithm updates may happen • How those changes will be tested and validated • What safeguards will ensure the AI remains safe and effective If the regulator approves that framework in advance, certain improvements can later be implemented without restarting the entire approval process each time. In simple terms: Instead of asking for permission after every improvement, you agree upfront on how improvements will happen responsibly. That changes the conversation completely. Because PCCP is not just about speed. It is about creating a system where: • Innovation remains accountable • Regulators maintain oversight • Patients benefit from continuously improving technology This is one of the first major regulatory frameworks designed specifically for adaptive AI systems, not static software. And it signals something larger: Healthcare regulation is beginning to evolve alongside intelligent technologies, rather than reacting years later. The concept is now live in the US. Europe is moving in a similar direction through parts of the AI Act. The larger question now is: How should other regulatory ecosystems including India’s Central Drugs Standard Control Organization(CDSCO) prepare for continuously learning medical AI systems? CliniExperts Services Pvt. Ltd. CliniExperts Research Services #AIinHealthcare #SaMD #RegulatoryAffairs #MedTech #DigitalHealth
-
Dr. Ashwini Kumar shared thisHow does a regulatory ecosystem evolve - quietly, but consistently? India’s medtech regulatory journey over the last decade tells a story that is often under-discussed. In 2017, the introduction of the Medical Devices Rules (MDR) fundamentally changed how devices were regulated in India. It was not just a policy update. It was a structural shift. A move toward: • Risk-based classification (Class A–D) • Defined licensing pathways • Alignment with global regulatory principles In fact, MDR 2017 introduced a comprehensive framework covering classification, manufacturing, import, clinical evaluation, and post-market surveillance, bringing India closer to global regulatory standards And the evolution did not stop there. Over the years, Central Drugs Standard Control Organization(CDSCO) has continued to build on this foundation: • Expansion of notified devices • Digitalization of approvals (SUGAM portal) • Strengthening of post-market oversight And now, with the 2025 draft guidance on medical device software, we are seeing the next phase. A system that now: • Clearly distinguishes between SiMD and SaMD • Introduces structured pathways for software-driven healthcare • Emphasizes quality systems, lifecycle management, and post-market monitoring This is not a sudden leap. It is a layered progression. From regulating devices… to regulating systems… to now regulating intelligent, adaptive technologies. What stands out is not just the pace of change. But the intent. A gradual shift from: Reactive oversight to Structured, forward-looking regulation And that is what builds credibility at a global level. Because strong industries are not built only on innovation. They are built on regulatory systems that evolve with it. Having worked closely with this ecosystem, one thing becomes clear: India is no longer just aligning with global frameworks. It is beginning to define its own. What, in your view, has been the most defining shift in India’s medtech regulatory journey so far? CliniExperts Services Pvt. Ltd. CliniExperts Research Services #MedTech #RegulatoryAffairs #HealthcarePolicy #DigitalHealth #IndiaHealthcare
-
Dr. Ashwini Kumar shared thisWhat if cancer could be detected before it even shows symptoms? In one of our recent conversations with Dr. Gurdeep S. Sethi M.D., we explored a fascinating advancement in early cancer detection - PanTum Detect, a simple blood test designed to identify tumors at a very early stage. What makes this approach interesting is not just the idea of early detection, but how it works. Instead of looking for tumors directly, the test leverages the body’s own biology, specifically macrophages, the immune system’s “scavenger cells.” These cells constantly circulate in the blood, picking up abnormal proteins from anywhere in the body, whether from infections or potentially from tumor activity. Using a patented EDIM (Epitope Detection in Macrophages) technology, this test analyzes what these macrophages have “collected,” offering a window into what may be happening inside the body, often before clinical symptoms appear. The potential here is significant: • Detecting cancer at Stage 0, 1, or 2 - where intervention can be far more effective • Moving from reactive diagnosis to proactive screening • Leveraging the immune system itself as a diagnostic tool Of course, like any emerging diagnostic innovation, parameters such as sensitivity, specificity, and clinical validation across populations will continue to define its real-world impact. But the direction is clear. The future of oncology may not just depend on better treatments, but on how early, how accurately, and how intelligently we can detect disease. Would you trust a simple blood test to tell you what your body hasn’t yet felt? CliniExperts Research Services CliniExperts Services Pvt. Ltd. #MedTech #Oncology #EarlyDetection #HealthcareInnovation #Diagnostics #ClinicalResearch
-
Dr. Ashwini Kumar reposted thisDr. Ashwini Kumar reposted thisHiring ERPNext / Frappe Developers with 4–5 years of experience to build and scale impactful solutions in the CRO space. If you’re passionate about Python, automation, and creating systems that matter — we’d love to connect. #Hiring #ERPNext #Frappe #PythonJobs #TechHiring #DelhiJobs #CliniExperts
-
Dr. Ashwini Kumar shared thisSiMD, SaMD, or an AI healthcare tool - are we classifying correctly, or assuming? In India’s evolving digital health landscape, this distinction is not just technical. It is regulatory. And getting it wrong does not lead to a small correction. It can impact your entire pathway - approvals, timelines, and in some cases, your licence to operate. I’ve seen this pattern often. A product is built with strong intent and solid technology. But somewhere along the way, classification is treated as a late-stage decision. Something to address after development. In reality, classification should be one of the earliest strategic decisions. Because it influences: • The regulatory pathway you follow • The level of evidence required • The documentation and validation approach • The time it takes to reach the market The challenge is that many digital health solutions today sit in grey areas. Is it: • Software in a Medical Device (SiMD)? • Software as a Medical Device (SaMD)? • Or an AI-enabled healthcare tool with clinical implications? The answer depends not on the technology itself, but on its intended use, risk profile, and impact on clinical decision-making. Regulation does not evaluate innovation. It evaluates responsibility. And clarity at the start often prevents complexity later. If you are building or deploying digital health solutions in India: At what stage do you believe classification should be finalised - early in development, or closer to defining regulatory strategy? CliniExperts Services Pvt. Ltd. CliniExperts Research Services #SaMD #SiMD #AI #healthcare #medtech
-
Dr. Ashwini Kumar shared thisWhat if your regulatory function operated like a full-fledged department, without the complexity of building one in-house? Across healthcare, pharma, MedTech, and nutraceutical businesses, I’ve observed a recurring gap: Regulatory affairs is often treated as a support function. Not as a strategic system. But today, navigating bodies like Central Drugs Standard Control Organization and Food Safety And Standards Authority Of India (Fssai) requires continuous alignment, not episodic intervention. Which is why we’re introducing something we’ve been thoughtfully building: CliniExperts Services Pvt. Ltd.’ Outsourced Regulatory Affairs Department A model designed to function not as an external vendor, but as an extended regulatory arm of your organization, bringing together multi-regulatory expertise, structured processes, and execution clarity within one integrated system. Because compliance today is not just about approvals. It’s about speed, predictability, and confidence in every decision you make. If you're building or scaling in a regulated environment, the real question is no longer whether you need regulatory support; but how strategically it is embedded into your growth journey. If you’re rethinking how regulatory can move from a bottleneck to a business enabler, I’d be glad to exchange perspectives. https://lnkd.in/gngeG9Q8 #RegulatoryAffairs #MedTech #HealthcareCompliance #DigitalHealth #HealthcareConsultingYour outsourced regulatory affairs department — CDSCO, FSSAI & cross-functional compliance, Always…Your outsourced regulatory affairs department — CDSCO, FSSAI & cross-functional compliance, Always…
-
Dr. Ashwini Kumar liked thisDr. Ashwini Kumar liked thisEntrepreneurship often begins with hustle, ambition, and the belief that success comes from doing it all yourself — but the most sustainable growth often comes when you learn to let go. In her latest reflection, WIN Executive Director Rebecca Takemoto shares how motherhood transformed the way she leads, builds teams, embraces imperfection, and navigates the many seasons of entrepreneurship. From letting go of perfection, to trusting others, to learning that grace, resilience, and adaptability may be the most important leadership skills of all — this is a deeply honest reflection on growth. Not just as a leader, but as a woman navigating ambition, family, identity, and purpose. And most importantly, a reminder that every woman’s story deserves to be honored, whether motherhood is part of that story or not. Read Rebecca’s full blog post: https://lnkd.in/gZaycZY4 Karen E. Todd, MBA, RD Heather Granato Michelle Martin Karen Howard Doug Reader Jan Mills Anand Swaroop Dr. Sybille Buchwald-Werner Crystal Webber, MS, RD Petra Erlandson Ewa Hudson #WomenInNutraceuticals #WINtogether #Leadership #Entrepreneurship #WomenInBusiness #Motherhood #LeadershipLessons #WomenLeaders #Community #PersonalGrowth
-
Dr. Ashwini Kumar liked this“Great teams don’t just achieve milestones—they build movements that create lasting impact.” Truly proud to see this recognition for a journey that has meant so much to all of us. Special appreciation to the entire Vaccines team at Pfizer India for bringing this vision to life with such commitment and heart. Moments like these reinforce why we do what we do—building something that goes beyond a launch to create lasting change. #PfizerProud #OPPIAnnualAwards #AdultImmunizationDr. Ashwini Kumar liked thisA proud leadership moment for Vaccines Medical, Pfizer India. Honoured to receive the Runner‑Up recognition at the OPPI Medical Excellence Awards 2025–26 for “Launch Excellence to Public Health Impact: Strengthening India’s Adult Immunisation Ecosystem”. This achievement reflects consistent leadership commitment to science‑driven decision‑making, responsible innovation, and long‑term public health value. Especially meaningful as this marks our second OPPI Medical Excellence recognition in succession—a testament to sustained excellence. A special note of thanks to Dr Santosh Taur, MD, DM, CMD for his visionary leadership and for championing science‑led, patient‑centric impact in adult immunization. Deep appreciation to Meenakshi Nevatia, Amit Agarwal, Dr. Pankaj Gupta, Nilesh Pendse, Manikantan Seshadrinathan, Sharad Goswami, Saral Gupta, Dr.Seema Pai, Manish Paliwal and the Leadership Team at Pfizer India for their strategic direction, trust, and unwavering support. Grateful to the India Vaccines team - Dr Mukundraj Keny, Dr. Sachin Choudhari, Dr Abhishek Tripathi, Arshiya Sehgal MD, Dr Joseph Immanuel, Anusha Gupta, MDS, Dr. Vishal Mitkari, Dr Praveenkumar Rajendran M.D., Dr. Gitika Jha, Dr. Durgesh Nandini, Rajashekhar Arra, Dr. Rashi Jaiswal, Sairam R R, Amol Dhiman, Jitender Sharma, Parth Mishra, Jacob Anand, Uma Balakrishnan, Dr Anuja Giri, Murtuza Stationwala and our cross‑functional partners across Regulatory, Clinical, Access, Policy—this OPPI recognition is truly a team win. Heartfelt thanks to Egemen Ozbilgili, MD, Mark Fletcher, and Bulent Taysi for their continued guidance, and global leadership. Proud of the journey. Focused on what’s next. #PFEColleague #OPPIMedicalExcellence #OPPIAnnualDay #PowerofPartnership #OPPIAnnualAwards #AdultImmunisation #PublicHealthImpact #MedicalLeadership
-
Dr. Ashwini Kumar liked thisDr. Ashwini Kumar liked thisHappening tomorrow! FDA will be taking industry questions on a proposed pilot program to assess how AI-enabled technologies can improve efficiency, speed, and quality of decision-making in early phase clinical trials. Register here: https://lnkd.in/ey-SRQ8X
-
Dr. Ashwini Kumar liked thisDr. Ashwini Kumar liked thisIndia continues to be one of the most attractive markets for global Medical Device companies, driven by its growing healthcare sector and vast opportunities. However, entering the Indian market requires careful regulatory planning under CDSCO and the Medical Devices Rules, 2017. From correct device classification and appointment of an authorized Indian agent to choosing the right MD forms and SUGAM submission pathway, every step plays a critical role in ensuring smooth market entry and regulatory compliance. Read the full article now on our website: https://lnkd.in/gvwQeRZK #MedicalDevices #CDSCO #MedicalDeviceRegulations #IndiaMarket #HealthcareIndustry #RegulatoryCompliance #CliniExpertsHow to Get a CDSCO Import License in India: A Step-by-Step Guide for Foreign Medical Device CompaniesHow to Get a CDSCO Import License in India: A Step-by-Step Guide for Foreign Medical Device Companies
-
Dr. Ashwini Kumar liked thisDr. Ashwini Kumar liked thisThe new augmentOR™ Portal makes collaboration smarter than ever with upgraded video editing and sharing features that help teams review cases more efficiently, highlight key moments, and capture insights in real time. Now available on both iPhone and Android, clinicians can use the Portal to access Performance‑Guided Surgery™ wherever they are, bringing greater flexibility and connectivity to the surgical workflow.
-
Dr. Ashwini Kumar liked thisDr. Ashwini Kumar liked this𝗣𝗖𝗢𝗦 𝗷𝘂𝘀𝘁 𝗯𝗲𝗰𝗮𝗺𝗲 𝗣𝗠𝗢𝗦. 𝗔𝗳𝘁𝗲𝗿 𝟭𝟰 𝘆𝗲𝗮𝗿𝘀 𝗮𝗻𝗱 𝟭𝟰,𝟯𝟲𝟬 𝗽𝗮𝘁𝗶𝗲𝗻𝘁 𝗮𝗻𝗱 𝗰𝗹𝗶𝗻𝗶𝗰𝗶𝗮𝗻 𝘀𝘂𝗿𝘃𝗲𝘆 𝗿𝗲𝘀𝗽𝗼𝗻𝘀𝗲𝘀, 𝘁𝗵𝗲 𝗿𝗲𝗻𝗮𝗺𝗲 𝗶𝘀 𝗼𝗳𝗳𝗶𝗰𝗶𝗮𝗹. The Lancet published the global consensus paper yesterday, with parallel announcement at the European Congress of Endocrinology in Prague. The new name, polyendocrine metabolic ovarian syndrome, replaces a term that was based on a 1930s surgical observation that turned out to be wrong. PMOS patients do not have pathological cysts. They have a population of follicles that fail to mature. 𝗪𝗵𝘆 𝘁𝗵𝗶𝘀 𝗺𝗮𝘁𝘁𝗲𝗿𝘀. The condition affects 1 in 8 women globally (more than 170 million people). Up to 70 percent of cases remain undiagnosed, in part because the gynecologic framing obscured the metabolic, endocrine, dermatologic, and psychological reality of the disease. The NIH first recommended a rename in 2012. It took international leadership led by Helena Teede AM at International Society of Endocrinology - ISE, a democratic Delphi process across 56 partner organizations, and direct patient advocacy involvement to make it stick. Women living with the condition were the drivers of change. Their advocacy, leadership, and lived experience shaped this outcome. For those of us who have spent more than a decade in this space (Chemical Resources (CHERESO) & Cepham Inc Furocyst® program began clinical work on PCOS in 2012 with a 208-subject randomized controlled trial), the rename is overdue scientific honesty. The condition was always insulin resistance, androgen dysregulation, and chronic low-grade inflammation, with reproductive consequences as one expression of a multi-system endocrine syndrome. 𝗣𝗠𝗢𝗦 𝗿𝗲𝗳𝗹𝗲𝗰𝘁𝘀 𝗮 𝘄𝗵𝗼𝗹𝗲-𝗯𝗼𝗱𝘆 𝗰𝗼𝗻𝗱𝗶𝘁𝗶𝗼𝗻, 𝗻𝗼𝘁 𝗷𝘂𝘀𝘁 𝘁𝗵𝗲 𝗼𝘃𝗮𝗿𝘆. For nutraceutical R&D, the rename has three implications: [1] Shift in formulation logic from PMOS as a fertility problem to metabolic-endocrine disorder with fertility, dermatologic, and psychological consequences. [2] Boader clinical endpoint selection: HOMA-IR, lipid panels, dermatologic scores, and validated QoL instruments belong alongside cycle regularity. [3] Claims framing has to follow the science. 𝗔 𝗻𝗼𝘁𝗲 𝗼𝗻 𝗺𝗮𝗹𝗲 𝗣𝗠𝗢𝗦. Emerging work suggests a male equivalent of the syndrome exists, particularly in first-degree male relatives of affected women. Insulin resistance, central adiposity, dyslipidemia, and early-onset androgenetic alopecia are the typical cluster. The shared genetic and metabolic architecture is real, even if the male phenotype remains less well characterized. STAT on the male form: https://lnkd.in/ehYRvuGS The Lancet consensus paper: https://lnkd.in/e5ezQ5v6 Pawan Kumar Sameer Joshi Christopher Lamb #WomensHealth #Endocrinology #PMOS #ClinicalResearch #NutraceuticalsPolyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus processPolyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process
-
Dr. Ashwini Kumar liked thisDr. Ashwini Kumar liked thisOne of the questions I get asked most often in fetal cardiology is: What does a prolonged fetal PR interval mean? The honest answer is, before we discuss what it means, we need to talk about whether the number we have is reliable. I have written a detailed acquisition guide covering the three main pulsed-wave Doppler methods for measuring the fetal mechanical PR interval: LV inflow/outflow, SVC/ascending aorta, and pulmonary artery/vein, along with tissue Doppler as a supplementary technique. The post covers: → Which fetal position each method requires → Angle of insonation, wall filter, sweep speed → Why PA/PV values run 6–15 ms higher than MV/Ao across gestation → Why SVC/Ao and MV/Ao give broadly similar values — and when that matters → When mPR measurement is actually indicated All clinical images are from our lab. There is also a free interactive guide linked in the post with normative charts, method bias data, and a full acquisition walkthrough. Read the full post here: https://lnkd.in/gs7XNRtf #FetalCardiology #FetalEchocardiography #PediatricCardiology #CongenitalHeartBlock #NeonatalLupus #FoetalMedicine #FetalArrhythmia #MaternalFetalMedicineMeasuring the Fetal PR Interval: Getting the Acquisition RightMeasuring the Fetal PR Interval: Getting the Acquisition Right
Experience & Education
-
CliniExperts Research Services
******* *** ***
-
************ ******** ********
******* *** ***
-
*** ****** *************
**** ** ********* ******* ********** *** ********** *******
-
*** ***** ********* ** ******* ********
**** ********** ********** ************* Research Scientist
-
-
******** ******* ******** ********
**** ********
-
View Dr. Ashwini’s full experience
See their title, tenure and more.
Welcome back
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
or
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
Publications
Recommendations received
2 people have recommended Dr. Ashwini
Join now to viewWebsites
- Company Website
-
http://www.cliniexperts.com/
Other similar profiles
-
Sanjay Puri
Sanjay Puri
ACCUPROBE HEALTHCARE AND DIAGNOSTICS PRIVATE LIMITED
603 followersDelhi, India
Explore more posts
-
Kiran Mazumdar Shaw
Biocon Group • 1M followers
𝐅𝐫𝐨𝐦 𝐩𝐡𝐚𝐫𝐦𝐚𝐜𝐲 𝐭𝐨 𝐢𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧 𝐡𝐮𝐛: 𝐖𝐡𝐲 𝐈𝐧𝐝𝐢𝐚 𝐧𝐞𝐞𝐝𝐬 𝐚 𝐫𝐞𝐠𝐮𝐥𝐚𝐭𝐨𝐫𝐲 𝐫𝐞𝐯𝐨𝐥𝐮𝐭𝐢𝐨𝐧 𝐢𝐧 𝐛𝐢𝐨𝐭𝐞𝐜𝐡. India aims to transition from a global pharmacy to an innovation hub by reforming its regulatory landscape. The focus is on AI-powered approvals, adaptive trials, fast-track pathways, and a single-window digital platform. Creating public market access for biotech startups and incentivizing investment are crucial to compete with China's advancements in drug innovation. My OpEd in today’s ET. https://lnkd.in/g7JyxnQs
1,138
55 Comments -
Preet Pal Singh
Jaidev Pharma Placement • 45K followers
Requesting 4 Candid Feedback : 💊 The Business of Conferences (India’s total CME market at ≈ $1.6 billion (~₹13,280 crore) in Indian – Boon, Bane, or Both? Dark Currency to White ? Every year, the Indian pharmaceutical industry spends crores of rupees sponsoring, organising, and attending high-profile doctor conferences — from ANCIPS, MediConclave, APICON, AIOC, PEDICON, IOACON, FOGSI Annual Conference, to CardioCon, DermaCon, and many more. What Really Happens at These Conferences? For Doctors 🩺 . Barring a few committed academicians who deliver lectures, present research papers, and share genuine scientific updates with slides, a large portion of attendees treat the event as… well… a networking getaway. . For many, it’s about meeting peers, exploring the exhibition stalls, and yes, enjoying the gala dinners, wines & cultural nights. . In between sessions, there’s often a mix of catching up with old friends and meeting new company representatives. For Senior Pharma Managers 👔 . Zonal, Regional, and National Heads attend to ensure their company’s visibility is maximised. . They meet key doctors, negotiate future business opportunities, and build relationships over coffee tables or banquet dinners. . Many also supervise the execution of sponsorship commitments — from ensuring the brand logo is visible on banners, to making sure the sponsored symposium runs as planned. For MRs, ASMs, and RSMs 🚶♂️ . Medical Representatives (MRs) usually manage stall activity, greet doctors, and distribute literature or samples. . Area Sales Managers (ASMs) coordinate the flow of visiting doctors, handle last-minute arrangements, and act as a bridge between field teams and the head office. . Regional Sales Managers (RSMs) often focus on higher-value relationship building — escorting key opinion leaders (KOLs) to sponsored events, facilitating introductions, and ensuring smooth logistics for VIP doctors. Pros of Conferences ✅ . Knowledge Sharing: Platform for genuine academic exchange (when it happens sincerely). . Relationship Building: Helps pharma teams strengthen trust with key doctors. . Brand Visibility: Strategic placements and sponsorships enhance recall. Networking: Facilitates doctor-to-doctor and doctor-to-pharma connections. Cons of Conferences ❌ . High Cost, Questionable ROI: Sponsorships run into lakhs or crores, but measurable returns are often vague. . Distraction from Core Purpose: Entertainment sometimes overshadows academic goals. . Overcrowded Branding: With dozens of companies vying for attention, differentiation is tough. . Fatigue Factor: Doctors & pharma teams attend multiple such events a year, reducing the novelty. The Bigger Question 🤔 💬 I’d love to hear from doctors, MRs, managers, and conference organisers — What’s your take on the real value of these conferences? #IndianPharma #PharmaMarketing #MedicalConferences #ANCIPS #APICON #FOGSI #CardioCon #Dermacon #PharmaIndustry #DoctorEngagement #PharmaSales #HealthcareMarketing
74
21 Comments -
Amit Mangal
Opulix Advisory Services • 15K followers
🩺 𝗙𝗿𝗼𝗺 𝗠𝗥𝗜 𝘁𝗼 𝗜𝗣𝗢! 📈 𝗔𝗮𝗿𝘁𝗵𝗶 𝗦𝗰𝗮𝗻𝘀 & 𝗟𝗮𝗯𝘀 — one of India’s most affordable and widely trusted diagnostic chains — is in active talks to raise ₹250 crore in pre-IPO funding. Built on a high-volume, low-cost model with deep presence in Tier II/III cities, Aarthi has quietly become a national player in radiology and pathology 𝘄𝗶𝘁𝗵 𝟳𝟱 𝗰𝗲𝗻𝘁𝗿𝗲𝘀 𝗴𝗿𝗼𝘄𝗻 𝗼𝗿𝗴𝗮𝗻𝗶𝗰𝗮𝗹𝗹𝘆 𝘄𝗶𝘁𝗵𝗼𝘂𝘁 𝗮𝗻𝘆 𝗱𝗲𝗯𝘁. This funding round signals growing investor confidence in value-led healthcare models — and could set the stage for another high-impact IPO in the diagnostics space. 🔬 #IPO #Diagnostics #AarthiScans #HealthcareFunding #PreIPO #HealthTech #InvestorWatch #AffordableHealthcare #IndianHealthcare Opulix Advisory Services Govindarajan V https://lnkd.in/gvM3rBnT
7
-
Debjyoti Chattopadhyay
Roche • 6K followers
Pharmaceutical companies play a crucial role in addressing India's cancer crisis by not only supplying medicines but also acting as strategic partners in enhancing access, affordability, and innovation. Here's why their involvement is pivotal: 🔑 Why Pharma’s Involvement is Essential 1. Bridging Innovation and Access: Pharma companies develop advanced therapies, yet without appropriate pricing and access structures, these treatments remain inaccessible. Their initiatives in tiered pricing, patient support programs, and innovative payment models can make life-saving treatments affordable. 2. Scaling Screening and Early Detection: Apart from medications, companies can enhance diagnostic facilities by funding mobile screening units, training oncologists, and collaborating with NGOs for early detection campaigns. Early diagnosis significantly boosts survival rates and reduces treatment expenses. 3. Data & Real-World Evidence (RWE): Given the fragmented nature of cancer reporting, pharma can collaborate to establish registries and real-world evidence platforms with hospitals, government bodies, and digital health startups. This aids in recognizing unmet needs, treatment effectiveness, and financial shortages. 4. Public–Private Partnerships (PPPs): Pharma firms are well-placed to collaborate with various health departments to integrate cancer care into public health initiatives, ensuring broader coverage, especially in rural and underserved regions. 5. Affordability and Innovative Financing: Innovative models like risk-sharing agreements, outcome-based pricing, and insurance partnerships can prevent patients from facing overwhelming out-of-pocket costs. Companies pioneering these approaches can redefine access to cancer care in India. 🚩 Critical Watchpoints - Avoid tokenism by integrating access initiatives into core commercial strategies. - Maintain transparency and trust through clear communication on pricing models and outcomes. - Ensure inclusivity by addressing pediatric cancers, women's cancers (such as cervical & breast), and rare cancers often overlooked. 🌍 The Bigger Picture By taking proactive steps, the pharmaceutical sector not only expands its market but also contributes to reshaping India's healthcare landscape towards equity and resilience. Cancer
2
1 Comment -
Darshil K.
CREDX • 7K followers
Healthcare Paradigm Shift: Beyond Blood Tests 🩸 Sushant Kumar - Genefitletics argues: • Microbiome > Blood biomarkers • Symptom tracking > Lab reports • 500,000 health transformations planned 👉 https://lnkd.in/gR_d4GGm 🌐 credx.club #Healthcare #DigitalHealth #Innovation
2
-
Shweta Gandhi
IIM Indore • 5K followers
𝐈𝐧𝐟𝐨𝐫𝐦𝐞𝐝 𝐂𝐨𝐧𝐬𝐞𝐧𝐭 𝐢𝐧 𝐈𝐧𝐝𝐢𝐚 - 𝐖𝐡𝐲 𝐈𝐬𝐧’𝐭 𝐢𝐭 𝐒𝐭𝐫𝐢𝐜𝐭𝐥𝐲 𝐅𝐨𝐥𝐥𝐨𝐰𝐞𝐝? Every patient deserves to truly understand their treatment, risks, and options. Yet, in India, poor patient adherence—linked to unclear or rushed consent—costs healthcare providers over ₹12,000 crore each year in avoidable complications and readmissions. What Makes Consent Truly “Informed”? > Capacity: The patient must be able to understand and make decisions about their care. > Clear Information: They need full details on treatments, risks, benefits, and alternatives. > Voluntary Choice: Their decision should be free from pressure or coercion. The Business Case for Better Consent > Reduced Risk: Strong consent processes cut litigation by 27% and improve patient satisfaction by 18% (AIIMS data). > Faster Claims: Proper documentation speeds up insurance processing. > Reputation Boost: Trustworthy hospitals attract more patients and medical tourists. However, there are challenges unique to India : > Hierarchical Doctor-Patient Relationships: Many patients hesitate to ask questions. > Family Influence: Decisions are often made by families, not just the patient. > Low Health Literacy: Many struggle to understand medical jargon. The main thing I want to say is that "informed consent" isn’t just a legal checkbox, but a way to build trust, improve outcomes, and stand out as a patient-first healthcare provider. By focusing on clear communication (like we do at NirogGyan | Smart Reports for Patients), voluntary choice, and thorough documentation, hospitals can make a real difference in patients’ lives, and their own success.
11
3 Comments -
Sheetal Arora
MANKIND PHARMA LTD • 76K followers
India’s pharma sector is standing at a rare convergence point, where policy, innovation, and access are finally aligning. As the world moves beyond the patent cliff, we have a unique opportunity to lead with both affordability and originality. The shift from ‘copy’ to ‘create’ is no longer a vision; it’s a necessity. With the right foundation in place, these are truly exciting times ahead for the Indian pharmaceutical industry. I’ve shared some thoughts in this piece with The Economic Times. Read more: https://lnkd.in/g59NSg9w #PharmaInnovation #IndianPharma #AffordableExcellence #FutureOfMedicine #HealthcareLeadership
540
41 Comments -
Raghava Rao
Camomile Healthcare • 12K followers
Apollo’s Strategic Restructuring: A Signal for the Future of Indian Healthcare? Apollo Hospitals’ bold move to demerge its digital health and pharmacy assets (Apollo 24|7 & Keimed) into a standalone listed entity marks a significant milestone—not just for the group, but for the broader healthcare ecosystem in India. What does this mean for the industry? This restructuring unlocks hidden value within Apollo’s integrated model, creating specialized, agile units that can independently scale and attract capital. For peers like Max Healthcare, Narayana Health, Fortis Healthcare, and Medanta, this raises important questions: 1. Should they pursue digital-health-first spin-offs to keep up? 2. Will focused verticals (like diagnostics, retail pharma, digital clinics) outperform integrated giants? 3. Is the Indian healthcare market now mature enough for multi-entity structures like in global markets? Apollo seems to be betting on a decentralized future where capital, growth strategies, and valuation metrics are tuned to the unique dynamics of each vertical—from hospitals to digital care to supply chains. As Camomile Healthcare, we see this as a trendsetting move—one that could redefine how healthcare conglomerates structure themselves in India. #ApolloHospitals #HealthcareTransformation #ValueUnlocking #HealthcareStrategy #IndianHealthcare #HealthTech #CamomileHealthcare #FutureOfHealthcare
88
8 Comments -
Ajay Kakar
Salve Pharmaceuticals Pvt Ltd • 16K followers
One Nation, One Medical Treatment. Healthcare access should not depend on income, influence, or geography. Yet in this year’s Budget, health receives only around 2% of total government expenditure — roughly ₹1 lakh crore. Under the National Health Policy 2017, India committed to spending 2.5% of GDP on public health. In 2026, we are still hovering around 0.5% of GDP. We are nowhere near our own target. Compare this globally: • US – 18% of GDP • UK – 12% • Germany – 13% • Sweden, Netherlands, Denmark, Japan, Spain – around 10% Because kyonki jaan hai toh jahaan hai. The consequences are visible: • Overcrowded government hospitals • Overworked doctors • Too few beds • Shortage of machines and medicines • Delayed treatments When families cannot wait, they turn to private hospitals. And one health emergency quickly becomes a debt emergency. Healthcare is not an expense. It is an investment in national productivity and human dignity. What reforms do you think India must prioritise to truly achieve “One Nation, One Medical Treatment”? #Healthcare #Budget2026 #PublicPolicy #IndiaGrowth #HealthReform #Leadership #NationBuilding
6
1 Comment -
Dom Bourgeon
Fiuza Bourgeon Advisory • 2K followers
💡 Post 2 | Pharma/Dia/MedTech’s Role Redefined Everyone wants to own the ecosystem. But in digital health, ownership is overrated — adaptation is everything. Pharma and diagnostics companies keep trying to build their own digital universes: portals, platforms, “connected ecosystems.” Meanwhile, the real action already happens inside existing ones — Epic, Salesforce Health Cloud, Apple HealthKit, Google Fit. The smartest players aren’t fighting the aggregators. They’re embedding in them. Sanofi, Roche, and Novo Nordisk now integrate their digital services through Health Cloud or App Orchard instead of creating new silos. That shift cuts infrastructure costs, speeds launches, and focuses energy where it matters: data, algorithms, and outcomes. Owning the user interface is no longer a competitive edge. Owning the insight behind that interface is. The new game for pharma and diagnostics isn’t building empires. It’s mastering coexistence — becoming indispensable inside someone else’s ecosystem. Because in digital health, control isn’t lost. It’s redefined. 🔍 References Roche & Salesforce Health Cloud partnership (2023) – focus on orchestration, not ownership. Sanofi–Google Cloud alliance for data platforms and AI drug design (2023). Novo Nordisk–Apple integration (HealthKit, 2022). Deloitte Life Sciences 2024 report: >70 % of pharma leaders plan to partner rather than build proprietary platforms. These are my reflections — not absolute truths — and I share them to spark discussion on how our industry can evolve. #DigitalHealth #PharmaInnovation #HealthTech #EcosystemStrategy #LifeSciences #DataStrategy #PlatformEconomy #HealthcareTransformation #AIinHealthcare
12
-
StartupCity Magazine
4K followers
Precision oncology startup 4baseCare has raised Rs 90 crore in the first close of its Series B round, co-led by Ashish Kacholia and Lashit Sanghvi, with continued support from Yali Capital. The fresh capital will help the company expand its genomics testing labs within hospital ecosystems and scale its AI-driven platform, OncoTwin, across India, the Middle East, Southeast Asia, Latin America, and Central Asia. Founded in 2023, 4baseCare combines genomic testing with real-world clinical data to enable more personalised cancer diagnosis and treatment. Its OncoTwin platform was recently selected for the MSK iHub program at Memorial Sloan Kettering Cancer Center, reinforcing its global ambitions. #4basecare #cancerinnovation #healthcarefunding #seriesbnews #oncologycare #genomicmedicine #aihealth #startupindia #healthtechindia #medicalai #cancerdiagnostics #globalhealthtech #investing #venturecapital #biotechstartup #precisionmedicine #healthcarestartup #fundingupdate
-
Finance Outlook India
3K followers
W Health Ventures achieves Rs 550 Crore First Close for Fund II The first closure of W Health Ventures' second fund, which focuses on healthcare, was announced at Rs 550 crore. The fund would invest in 8–10 healthcare businesses with a target corpus of around Rs 630 crore. Read More: https://lnkd.in/ectecHqv W Health Ventures #healthcarebusinesses #deliveryinitiatives #digitalhealth #healthcareservices
3
-
The Unicorn Magazine
17K followers
W Health Ventures announces Rs 550 Cr First Close for Fund II to Power India’s Healthcare Innovation Founded in 2019, led by Pankaj Jethwani, MD MBA, W Health Ventures is doubling down on healthcare innovation with the Rs 550 Cr first close of its Rs 630 Cr Fund II. * Model: Company creation & incubation * Focus: AI-healthcare, chronic care, oncology, geriatrics, preventive care * Cheque Size: Rs 30-50 Cr * Portfolio: Wysa, BeatO & cross-border health ventures (India-US) * Plan: Back 8-10 early-stage startups From building ventures from scratch to scaling impact-driven healthcare models, W Health is shaping a greener, tech-enabled future of care - where innovation meets accessibility. Gaurav Porwal | Harshit Tolasaria | Bhavesh Hemani | Tushar Sadhu | Anjali Menon | Ajay Sondhi | Amit Acharya 👉Follow The Unicorn Magazine for India’s startup world decoded-funding drops, founder stories, and fresh moves, daily under 100 words. #WHealthVentures #HealthcareStartups #Highlights #StartUpNews #TheUnicornMagazine
183
34 Comments -
D.C. Chetan
Benaka Indsol • 25K followers
Financial Due Diligence in Healthcare M&A and Expansion Projects Mergers, acquisitions, and hospital expansions are reshaping the healthcare landscape in India and across emerging markets. But behind every successful transaction lies one critical process — financial due diligence (FDD). It’s the stage where vision meets validation, and where the true value of a healthcare asset is revealed. For investors and acquirers, FDD is more than just reviewing balance sheets. It’s about understanding how a hospital operates — its revenue mix, patient inflow trends, payor contracts, and cost efficiency. A well-conducted due diligence uncovers not only the financial health of the institution but also its capacity for sustainable growth. In healthcare, cash flow analysis is especially important. Unlike other sectors, hospitals face unique variables — delayed insurance reimbursements, seasonal patient loads, and high equipment maintenance costs. Investors look for stability in EBITDA margins, predictable cash inflows, and responsible debt management before making a decision. When it comes to expansion or brownfield projects, due diligence also focuses on scalability — assessing whether the existing infrastructure, compliance systems, and human resources can support growth. Lenders and private equity firms often evaluate clinical governance, regulatory adherence, and brand reputation alongside the financial numbers. Equally critical is verifying ownership structures, outstanding liabilities, and potential legal exposures. Even small oversights here can lead to large financial risks post-acquisition. That’s why sophisticated investors rely on multidisciplinary teams — combining finance, legal, technical, and clinical experts — to ensure a 360-degree assessment. In essence, financial due diligence is not about skepticism; it’s about strategic clarity. It gives both buyers and sellers a shared understanding of value, risk, and opportunity. A transparent and well-documented due diligence process builds confidence, accelerates negotiations, and sets the foundation for a smoother integration. Healthcare is a sector built on trust — and that trust begins with due diligence. 📞 Please call us at 8861794443 or 9663383550, or visit 🌐 www.benakahealthcare.com for more details. #HealthcareFinance #HospitalProjects #HealthcareMergers #DueDiligence #BenakaHealthcare #HealthcareIndia #HospitalInvestments #HealthcareLeadership #MergersAndAcquisitions #HealthcareGrowth
3
-
Rishi Bhojnagarwala
Caddy - India’s GLP1 Companion • 4K followers
Semaglutide is now off patent. Will the GLP-1 market explode in India? Everyone assumes the answer is price. Cheaper drugs → more users → massive adoption. But reality is already telling us a different story. Over the last 12–18 months, GLP-1s have entered India meaningfully. And yet: 👉 The top-selling drug today is Mounjaro (Tirzepatide) — which isn’t going off patent anytime soon. 👉 From a pure weight loss standpoint, it’s already preferred over semaglutide. 👉 Early trends show Mounjaro sales > Ozempic + Wegovy combined. So clearly, price isn’t the only driver. India has <500k GLP-1 users today. North America? ~40 million users in ~5 years. This isn’t a pricing gap. This is an adoption gap. Because the real barriers are far more human: Low awareness (most people still don’t understand what GLP-1 actually does) Stigma (injections = extreme / dangerous / “last resort”) Narrative problem (overly clinical, zero relatability) Fragmented experience (no structured support post-prescription) And then comes the biggest one: 👉 Judgment. First, you’re judged for being overweight. Then, if you seek help — you’re judged again for “taking shortcuts.” So even if semaglutide becomes cheaper… Will that fix hesitation? Will that fix stigma? Will that fix confusion? Unlikely. GLP-1 doesn’t just need affordability. It needs acceptability. And that requires a shift in how we talk about it: From: Shortcuts, Quick fixes, Vanity weight loss To: Metabolic health, Biology-not willpower, Structured- supported journeys GLP-1 isn’t replacing discipline. It’s making discipline possible. If this category has to scale in India, it has to grow responsibly: with empathetic communication with real-world support systems with Indian context (food, habits, lifestyle) Not just prescriptions. Because adoption won’t come from price drops. It will come from trust. And whoever solves that… Will define the next decade of weight loss in India. #GLP1 #ObesityCare #HealthTech #MetabolicHealth #IndiaHealth #ozempic #mounjaro #peptides #semaglutide #tirzepatide #retatrutide Dr. Reddy's Laboratories MANKIND PHARMA LTD Novo Nordisk Cipla SUN PHARMA Lupin Emcure Pharmaceuticals Limited Zydus Group Torrent Pharmaceuticals Ltd Alkem Laboratories Ltd. ERIS Lifesciences Amal Kelshikar Geena Malhotra Erez Israeli Swati Dalal V Krishnakumar "KK" Alok Malik Kirti Ganorkar Dr. Vikas Gupta Dr Akhilesh Sharma - MD, FRCP(Liverpool)CClin((USA),CPV (U.K) Sandeep Singh Vikrant Shrotriya
4
2 Comments -
Sushant Kumar
Genefitletics • 7K followers
Since 2020 onwards, there is an influx of healthtech companies offering diabetes reversal programs with a hope to reverse disease( & raise VC money ). However these programs have been based on flawed approach of suppressing Hba1c levels & have no relevance to alteration in biochemistry behind onset of type 2 diabetes No wonder, incidence of type 2 diabetes is increasing at an accelerated pace with no improvement in glycemic control of patients suffering from this life threatening metabolic syndrome Let us discuss this in detail.Hba1c is nothing but glycated hemoglobin -Glucose stuck on your hemoglobin.Sugar & glucose are sticky, they stick to proteins & enzymes, making them dysfunctional Hemoglobin is protein in red blood cells(RBC) that creates a zone near blood vessels walls to allow endothelium derived Nitric oxide to function Nitric oxide is a signalling molecule, produced via either endothelial cells or oral microbiome pathway, that regulates glucose uptake by activating GLUT 4, a protein that goes to cell membrane binds to glucose, clear it from the circulation & transport inside the cells for storage or energy High sugar glycates your hemoglobin & produces advanced glycation end products(AGE) that leads to oxidative stress, production of free radicals & damages hemoglobin & red blood cells(RBC), altering the structure & function of RBC & impairing their ability to transport oxygen. This damage to RBC known as hemolysis, allows free hemoglobin to enter the plasma that scavenges & inhibits Nitric oxide activation Hemolysis also leads to release of enzyme Arginase-1 that metabolises L-arginine, a substrate required to produce nitric oxide via endothelial pathway, leading to functional loss of nitric oxide production. Besides, high sugar can make endothelial nitric oxide synthase dysfunctional, resulting in Nitric oxide deficiency Without nitric oxide, your body cannot clear glucose from the circulation & thereby suppressing Hba1c by eliminating carbs or focussing too much on protein does not work. Rather excess protein could be counter intuitive & impair insulin signalling pathways You need to reinstate Nitric oxide production. If you are consuming too much sugar & your endothelial cells have become dysfunctional(early signs are hypertension & high blood pressure), at least focus on improving your oral health by rebalancing your oral microbiome. With compromised oral health, you cannot have glycemic control. Diabetes reversal programs that do not focus on oral health is just a waste of time & money. Citations https://lnkd.in/gdwvQz9s https://lnkd.in/dsEi4GUx https://lnkd.in/gNQsqBMB #type2diabetes #hba1c #nitricoxide #oralmicrobiome #gutmicrobiome Sakshi Bali Shashi Shekhar M. Dr Kamal Karnatak Rajesh Pandit Professor Dr. Srivats Bharadwaj Ankit Jain, Ph.D.
6
-
Dr Rahul Singh Amritraj
GIMS Centre for Medical… • 9K followers
🇮🇳 India is stepping into a new era of healthcare innovation. The Union Budget 2026–27 sends a strong signal with: • ₹20,000 crore for private-sector–led R&D and innovation • ₹10,000 crore Biopharma Shakti initiative to expand clinical trials and biologics • Strategic upgradation of CDSCO to match global regulatory timelines This is more than policy. This is intent to lead globally. At the International Innovation Circuit, our mission is aligned with this national vision—connecting doctors, innovators, startups, regulators, and investors to translate policy momentum into clinically validated, regulatory-ready, globally scalable solutions. India is no longer just a manufacturing base. India is designing for the world. The ecosystem is ready. The circuit is forming. The time is now. #InternationalInnovationCircuit #IndiaDesignsForTheWorld #HealthcareInnovation #MedTech #Biopharma #StartupIndia #CDSCO #BiopharmaShakti
20
-
Dr. Vishal Gandhi PhD,MBA
BIORx Venture Advisors Pvt… • 20K followers
We at BIORx Venture Advisors Pvt. Ltd., Indian Healthcare Angels are thrilled to announce a 𝗦𝘁𝗿𝗮𝘁𝗲𝗴𝗶𝗰 𝗚𝗿𝗼𝘄𝘁𝗵 𝗠𝗶𝗹𝗲𝘀𝘁𝗼𝗻𝗲𝘀 𝗳𝗼𝗿 𝗼𝗻𝗲 𝗼𝗳 𝗼𝘂𝗿 𝗣𝗼𝗿𝘁𝗳𝗼𝗹𝗶𝗼 𝗖𝗼𝗺𝗽𝗮𝗻𝘆 - 𝗟𝗶𝘃𝗼𝗳𝘆 (𝟮+ 𝘆𝗲𝗮𝗿𝘀 𝗼𝗳 𝗥𝗲𝗹𝗮𝘁𝗶𝗼𝗻𝗮𝗹 𝗩𝗶𝗻𝘁𝗮𝗴𝗲 𝘄𝗶𝘁𝗵 𝗕𝗜𝗢𝗥𝘅 𝗚𝗿𝗼𝘂𝗽), a pioneering 𝗗𝗶𝗴𝗶𝘁𝗮𝗹 𝗛𝗲𝗮𝗹𝘁𝗵 & 𝗪𝗲𝗹𝗹𝗻𝗲𝘀𝘀 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺, marking a significant step forward in transforming how chronic conditions are managed in India and beyond. Here's what makes this partnership impactful: • 𝗣𝗲𝗿𝘀𝗼𝗻𝗮𝗹𝗶𝘇𝗲𝗱 𝗰𝗮𝗿𝗲 𝗮𝘁 𝗦𝗰𝗮𝗹𝗲 – Livofy empowers individuals to reverse chronic conditions like 𝗗𝗶𝗮𝗯𝗲𝘁𝗲𝘀, 𝗣𝗖𝗢𝗦, 𝗧𝗵𝘆𝗿𝗼𝗶𝗱, and 𝗢𝗯𝗲𝘀𝗶𝘁𝘆 through personalized nutrition and lifestyle interventions. • 𝗕𝗮𝗰𝗸𝗲𝗱 𝗯𝘆 𝗦𝗰𝗶𝗲𝗻𝗰𝗲, 𝗲𝗻𝗮𝗯𝗹𝗲𝗱 𝗯𝘆 𝗧𝗲𝗰𝗵 – AI-driven insights and real-time digital progress tracking form the backbone of Livofy’s digital health experience. • Led by 𝗖𝗲𝗿𝘁𝗶𝗳𝗶𝗲𝗱 𝗘𝘅𝗽𝗲𝗿𝘁𝘀 – A team of certified nutritionists and health coaches drive lasting outcomes for patients across geographies. • 𝗥𝗲𝗰𝗼𝗴𝗻𝗶𝘇𝗲𝗱 𝗯𝘆 𝗞𝗲𝘆 𝗦𝘁𝗮𝗸𝗲𝗵𝗼𝗹𝗱𝗲𝗿𝘀 – Livofy recently 𝗿𝗮𝗶𝘀𝗲𝗱 𝗳𝘂𝗻𝗱𝗶𝗻𝗴 from Indian Healthcare Angels members, being 𝗙𝗮𝗺𝗶𝗹𝘆 𝗢𝗳𝗳𝗶𝗰𝗲 of a 𝗹𝗲𝗮𝗱𝗶𝗻𝗴 𝗣𝗵𝗮𝗿𝗺𝗮 𝗰𝗼𝗺𝗽𝗮𝗻𝘆, validating its clinical and commercial relevance. It also received funding from Pontaq Ventures under the 𝗟𝗲𝗮𝗽 𝗔𝗵𝗲𝗮𝗱 𝟭 cohort, an initiative supported by STPI - Software Technology Parks of India, Government of India. 𝗥𝗲𝗰𝗲𝗻𝘁 𝗕𝘂𝘀𝗶𝗻𝗲𝘀𝘀 𝗠𝗶𝗹𝗲𝘀𝘁𝗼𝗻𝗲𝘀 Livofy has recently expanded its strategic partnerships by onboarding another leading pharmaceutical company in India, marking a significant step forward in its product-to-scale journey. Additionally, the team has successfully partnered with one of the top 𝗜𝗻𝘀𝘂𝗿𝗮𝗻𝗰𝗲 companies based in the 𝗨𝗔𝗘, which strengthens its global footprint. These collaborations go beyond capital; they are about accelerating the adoption of evidence-based, tech-enabled chronic care solutions at scale across India and beyond. Kudos to Sahil Pruthii and the entire Livofy team for their unwavering commitment to health outcomes and accessibility! We are proud to be Livofy ’s trusted partner as they continue to shape the future of digital healthcare in India. Together, we are reimagining chronic care one patient at a time. Our BIORx Venture Advisors Pvt. Ltd. Indian Healthcare Angels and VEOCAP Ventures Team, Bharat Das Harshit Agarwal Awdhesh Kumar Shukla Abhishek Raj Srivastava Mayank Srivastava Priyanshu Singh Follow our journey BIORx Venture Advisors Pvt. Ltd. https://biorx.in Indian Healthcare Angels – https://iha.vc VEOCAP Ventures – https://veocap.com/ Prem Barthasarathy Divyasree Krish Arvind Kumar Subodh Sachan Amit Verma Dr. Praveen Dwivedi TiE Delhi-NCR Shyam Kumar #BIORxVenture #STPI #TiEDelhiNCR #BIRAC #VeocapVentures #IndianHealthcareAngels
99
7 Comments
Explore collaborative articles
We’re unlocking community knowledge in a new way. Experts add insights directly into each article, started with the help of AI.
Explore MoreView Dr. Ashwini’s full profile
-
See who you know in common
-
Get introduced
-
Contact Dr. Ashwini directly